2 results
Approved WMOCompleted
Part 1: The primary objective is to investigate if the RNFL-ac in PD patients differs significantly from the RNFL-ac in healthy controls.Secondary Objectives are:1) to investigate if the RNFL-ac can be used to differentiate PD patients from healthy…
Approved WMOCompleted
To determine the conversion rate of PR to CR (i.e. PET negativity) after a single dose of 90Y-ibritumomab tiuxetan (a dose of 14.8 MBq/kg or 0.4 mCi/kg, max 1184 MBq or 32mCi) in patients with grade 1-3a, stage II, III or IV follicular lymphoma with…